Medical Device Submissions Workshops – Investigational Device Exemption (IDE)
8:30 am – 5:15 pm ET
February 5, 2025
Gain exclusive access to FDA and industry experts who will guide you through the critical IDE medical device submissions process step-by-step!
Medical Device Submissions Workshops – Investigational Device Exemption (IDE)
8:30 am – 5:15 pm ET
February 5, 2025
Medical Device Submissions Workshops – Investigational Device Exemption (IDE)
8:30 am – 5:15 pm ET
February 5, 2025
Join AdvaMed on February 5, 2025 for the Medical Device Submissions Workshop: Investigational Device Exemption (IDE)! This comprehensive workshop will provide you with in-depth guidance on the latest FDA regulations impacting the submission process and will help medtech professionals understand what’s needed for approval on their new technologies. This knowledge can expedite the journey to clinical trials and eventually to market, giving companies a competitive advantage.
The IDE Workshop offers hands-on learning through case studies, interactive discussions, and practical exercises, guiding attendees through the IDE submission process. We’re excited to offer a hybrid format that creates a comprehensive and interactive experience, while providing exclusive access to the FDA and leading industry experts for those attending in our Washington, D.C. office. If you’re new to medtech regulatory affairs, or looking to strengthen your foundational knowledge, this is the perfect event for you so register today!
Who should attend?
These workshops are valuable for anyone aiming to streamline the regulatory process, reduce submission risks, and confidently bring their device to market such as:
- Medical device professionals new to the FDA regulatory submission process
- Regulatory Affairs Professionals
- Regulatory Compliance Professionals
- Quality Assurance Professionals
- Regulatory Affairs Rotational Associates
View the 2025 IDE agenda below or download it here.
Join the mailing list to receive the latest news and updates on the 2025 Workshops.
IDE Submissions Workshop
*Schedule reflects Eastern Time
Time | Session Name |
---|---|
8:30 – 9:00 am | Registration Check-In and Continental Breakfast |
9:00 – 9:05 am | Welcome and Introductions |
9:05 – 10:00 am | What Is an IDE? Anne Talley, Chemical Engineer, FDA – Regulatory Context – When is an IDE needed? – Roles of sponsors, investigators and IRBs – The IDE Application and Helpful Tips |
10:00 – 11:00 am | Developing an IDE Strategy Tony Blank, Senior Director of Regulatory Affairs, AtriCure – What to consider and when – Preclinical testing before human studies – Making the best use of pre-submission meetings – Using foreign data in a US submission – Characteristics of a successful IDE submission |
11:00 – 11:15 am | Break |
11:15 am – 12:30 pm | Preparing the Technical & Functional Aspects of an IDE Blake Wilson, Partner, Global Regulatory, Hogan Lovells – Monitoring – Consenting of patients – Enrollment requirements – Adverse event reporting – Sponsor records and reports – Investigator records and reports – Protocol deviations |
12:30 – 1:30 pm | Networking Lunch |
1:30 – 2:15 pm | Regulatory Compliance During Study Conduct Tony Blank, Senior Director of Regulatory Affairs, AtriCure – Clinical study reports (interim and final) – Dissemination to the medical community and to regulators – Incorporation into pre-market submissions – Assessment of impact to product labeling – Requirements for registering trials on CT.gov |
2:15 – 3:00 pm | Reporting Results Blake Wilson, Partner, Global Regulatory, Hogan Lovells – Clinical study reports (interim and final) – Dissemination to the medical community and to regulators – Incorporation into pre-market submissions – Assessment of impact to product labeling – Requirements for registering trials on CT.gov |
3:00 – 3:15 pm | Break |
3:15 – 4:00 pm | Optimizing the Pre-Submission Meeting Tony Blank, Senior Director of Regulatory Affairs, AtriCure – What to consider and when – Preclinical testing before human studies – Making the best use of pre-submission meetings – Using foreign data in a US submission – Characteristics of a successful IDE submission |
4:00 – 4:45 pm | BIMO Inspections Amrin Chowdhury, Health Scientist, FDA – The purpose of a BIMO inspection – When and how a BIMO inspection occurs – Preventing findings and responding to findings – Typical and atypical observations – cautionary tales from the field |
4:45 – 5:15 pm | Speaker Q&A |
5:15 pm | Adjournment |
Join medical device submissions experts and FDA officials who will provide essential guidance through the IDE submission process.
Additional speakers will be added soon. Join our mailing list to be notified when all speakers are announced.
Meet the Speakers
Tony Blank, Senior Director of Regulatory Affairs, AtriCure
Tony Blank is the Senior Director of Regulatory Affairs at AtriCure. He is formerly the cofounder of Barton & Blank, a regulatory consulting firm specializing in providing strategic and tactical regulatory support for medical devices and combination products. Previously, Blank spent 12 years at Boston Scientific Corp. Under his leadership of the cardiovascular regulatory teams, Boston Scientific obtained numerous regulatory approvals for cardiovascular medical devices and combination products—among these being worldwide regulatory approvals for drug-eluting stents, implantable cardioverter defibrillators (ICD) and cardiac resynchronization therapy defibrillators (CRT-D), cardiac pacemakers and cardiac resynchronization therapy pacemakers (CRT-P), and detachable coils for peripheral embolization. Blank has been an active representative for the medical device industry and the regulatory profession on numerous policy issues working with AdvaMed. Among these activities has been participation in numerous Industry Working Groups including the Pediatric Devices, Advertising and Promotion, and Reprocessing Working Groups (each of which he co-chaired).
Amrin Chowdhury, Health Scientist, FDA
Amrin Chowdhury is a Health Scientist in CDRH’s Office of Clinical Evidence and Analysis (OCEA) at FDA. She joined the FDA in 2022 serving as a Policy Analyst within OCEA and currently, a member of the CDRH Bioresearch Monitoring Program (BIMO). Her work in BIMO focuses on bioresearch monitoring review and directing inspection of Premarket applications, which can include Premarket Approval Applications (PMAs), Premarket Notifications (510ks), Humanitarian Device Exemptions (HDEs), and De Novos. Prior to joining the FDA, Amrin served roles as a Project Manager, Clinical Research Associate, and Data Manager for various Phase I – Phase III drug clinical trials across different organizations, including Foundation for the National Institutes of Health, Leidos Biomedical, Inc., and EMMES Corporation.
Amrin received a bachelor’s degree in biology from George Mason University and a master’s in health science from George Washington University.
Anne Talley, Chemical Engineer, FDA
Anne Talley is a Chemical Engineer in the Division of Clinical Policy and Quality within the Office of Clinical Evidence and Analysis (OCEA) in the Center for Devices and Radiological Health (CDRH) at FDA. Anne has over 7 years of experience at FDA, both as a Lead Reviewer/Team Lead in the Office of Orthopedic Devices (OHT6) and within OCEA.
Blake Wilson, Partner, Global Regulatory, Hogan Lovells
Blake Wilson helps medical device, drug, and biologic companies successfully navigate FDA’s evolving regulatory landscape. With a focus on premarket submissions and clinical trial design and conduct, Blake helps sponsors plan their product development strategy and minimize regulatory risks.
When advising companies, Blake draws on years of experience practicing in front of the FDA. He has assisted clients across a wide range of submissions (e.g., presubmissions, investigational products, combination products, humanitarian/orphan products, marketing applications, breakthrough requests) with a focus on novel treatments. When feedback from the agency is needed, Blake helps sponsors craft a well-tailored regulatory strategy and is effective at presenting the plan to FDA. He also prepares sponsors for advisory panel hearings.
Attendees joining us in person will come to AdvaMed’s office located at 1301 Pennsylvania Ave NW Suite #400, Washington, D.C. 20004.
This event is offered both virtually and in-person to maximize convenience. Please note that in-person and virtual pricing is the same.
Check to see if your company is an AdvaMed member here.
- AdvaMed Member: $925
- AdvaMed Accel Member: $675
- Non-Members: $1,125
- Government/Academic/Nonprofit: $675
Learn more about the other Medical Device Submissions Workshops focused on the 510(k) and De Novo and Investigational Device Exemption process.
510(k) and De Novo Submissions Workshop
February 3-4, 2024
Gain strategies for assembling and streamlining effective 510(k) and De Novo submissions and obtain insight into FDA’s perspective on the 510(k) and De Novo review process during this interactive two-day workshop. This workshop will cover:
- FDA guidance for 510(k)
- Different types of 510(k)s
- Tips on interacting with FDA during the 510(k) review process
- De Novo overview and strategy
PMA Submissions Workshop
February 6-7, 2024
Using real-world case studies, this workshop will walk you through the practical steps of filing a PMA and offer you actionable insights on how to best navigate the PMA submission process. steps required, best practices and preparation for inspection will be covered throughout this workshop. This workshop will cover:
- Steps to develop a PMA submission strategy
- Preparation needed for an advisory panel meeting
- Tips to prepare for an inspection
- How to deal with unexpected clinical outcomes, animal test results and adverse panel recommendations
- Management of approved PMAs
Hear From Us
Sign up to receive emails highlighting our upcoming events, early registration savings, and engagement opportunities for the medical technology community.